Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul;13(7):e0057125.
doi: 10.1128/spectrum.00571-25. Epub 2025 May 22.

Performance of BIOFIRE FILMARRAY pneumonia panel in suspected pneumonia: insights from a real-world study

Affiliations

Performance of BIOFIRE FILMARRAY pneumonia panel in suspected pneumonia: insights from a real-world study

Mona Mustafa Hellou et al. Microbiol Spectr. 2025 Jul.

Abstract

Pneumonia may be caused by a diverse group of microorganisms; however, a microbiologic diagnosis is not universally made. Molecular tests such as the BIOFIRE FILMARRAY Pneumonia Panel (BF-PP) offer the possibility of rapid identification of potential pneumonia pathogens. This retrospective analysis was conducted as a sub-study of a recently published randomized controlled trial. Specimens from patients with suspected pneumonia were tested by the BF-PP, with results compared to cultures. The overall BF-PP positivity rate was 44.8% (252/563), and was higher [64.6% (164/254)] in specimens from patients ultimately diagnosed with pneumonia. Discrepancies between the BF-PP and cultures were most common for Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus agalactiae. Positive percent agreement (PPA) and negative percent agreement (NPA) between the BF-PP and culture were 91.4% (CI 86.3%-94.9%) and 83.6% (CI 79.5%-87.2%), respectively. For most bacteria, a correlation between high genomic abundance (genomic copies/mL) reported from the BF-PP and culture growth abundance was found. In specimens from patients ultimately diagnosed with pneumonia, clinical consistency-assessed based on whether BF-PP results aligned with associated culture results-was 79.9% and was highest for bronchoalveolar lavage fluid specimens. The BF-PP has reliable analytical performance and offers the potential advantage over conventional cultures of providing higher detection rates and more rapid results. Interestingly, despite the use of this advanced molecular diagnostic tool, one-third of pneumonia cases remained without a microbiologic etiology.IMPORTANCEThis study evaluates the BIOFIRE FILMARRAY Pneumonia Panel by comparing its performance to conventional cultures in a real-world patient population (including patients ultimately diagnosed as not having pneumonia) using different types of specimens. Findings show a higher detection rate of microorganisms with the panel compared to cultures, suggesting that this test could aid in tailoring treatments for pneumonia. However, challenges remain and require further study, including distinguishing true pathogens from colonizing microorganisms and determinig why one-third of patients diagnosed with pneumonia still lacked a microbiologic etiology.

Keywords: BIOFIRE; analytical performance; concordance; negative percent agreement; pneumonia; positive percent agreement.

PubMed Disclaimer

Conflict of interest statement

R.P. reports grants from MicuRx Pharmaceuticals and bioMérieux and is a consultant to PhAST, Day Zero Diagnostics, DEEPULL DIAGNOSTICS, S.L., Nostics, HealthTrackRx, bioMérieux, and CARB-X. R.P. has a patent on Bordetella pertussis/parapertussis PCR issued, a patent on a device/method for sonication, a patent on PET imaging of bacterial infection with a PET probe filed, and a patent on an anti-biofilm substance issued. R.P. receives honoraria from Up-to-Date and the Infectious Diseases Board Review Course. A.V. reports grants from bioMérieux and Moderna and is an inventor for Mayo Clinic Travel App interaction with Smart Medical Kit and Medical Kit for Pilgrims. Dr. Patel and Dr. Virk received funding from bioMérieux for this study. All other authors declare no competing interests.

Similar articles

References

    1. Musher DM, Abers MS, Bartlett JG. 2017. Evolving understanding of the causes of pneumonia in adults, with special attention to the role of pneumococcus. Clin Infect Dis 65:1736–1744. doi: 10.1093/cid/cix549 - DOI - PMC - PubMed
    1. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, Cooley LA, Dean NC, Fine MJ, Flanders SA, Griffin MR, Metersky ML, Musher DM, Restrepo MI, Whitney CG. 2019. Diagnosis and treatment of adults with community-acquired pneumonia. an official clinical practice guideline of the american thoracic society and infectious diseases society of America. Am J Respir Crit Care Med 200:e45–e67. doi: 10.1164/rccm.201908-1581ST - DOI - PMC - PubMed
    1. Theodosiou AA, Jones CE, Read RC, Bogaert D. 2023. Microbiotoxicity: antibiotic usage and its unintended harm to the microbiome. Curr Opin Infect Dis 36:371–378. doi: 10.1097/QCO.0000000000000945 - DOI - PMC - PubMed
    1. Gadsby NJ, Musher DM. 2022. The microbial etiology of community-acquired pneumonia in adults: from classical bacteriology to host transcriptional signatures. Clin Microbiol Rev 35:e0001522. doi: 10.1128/cmr.00015-22 - DOI - PMC - PubMed
    1. Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, Reed C, Grijalva CG, Anderson EJ, Courtney DM, et al. 2015. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med 373:415–427. doi: 10.1056/NEJMoa1500245 - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources